10 August 2018
In 2018, the number of pharmaceutical companies believing that the most effective way to reduce the share of imported drugs is further restriction or ban on participation of foreign producers in public procurement, increased to 63%.
This information is provided by Deloitte, which this year conducted a survey among 52 Russian and foreign manufacturers of original drugs and generics, as well as pharmaceutical distributors. According to the analysis, for a year the priority of this measure increased, having risen in the corresponding rating from the fourth to the first position. A year earlier, the priority was to encourage foreign manufacturers to switch to full-cycle production by benefits and preferences. According to the results of the survey, only 29% of respondents now consider this measure effective, therefore, it moved down to the third position of the rating.
According to Oleg Berezin, the partner of Deloitte, the changes in the respondents’ assessments occurred most likely because the companies saw how effectively the “third wheel” rule has been working for state purchases since 2016. This rule excludes imported medicines from bidding, if there are proposals for the supply of at least two drugs produced in Russia. Since January 1, 2017, to obtain the status of a local product it is required to produce a finished dosage form in Russia.
Among other government measures to reduce the share of imported drugs are the additional procedures for registration of medicines approved and produced abroad. This year, 29% of respondents considered them effective.Print
09 July 2020
08 July 2020
08 July 2020
07 July 2020